Search
for
Sort by
Research 31–60 of 1000+
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy
- Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients
- Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series
- Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline
- Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
- Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
- “Arrow” sign: A rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors
- Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
- Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series
- The Double-Edged Sword of Epidermal Growth Factor Receptor Inhibitor: Rash as Toxicity and Prognostic Marker
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- BI02 (P97): Epidermal growth factor receptor inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
- Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations
- 308 Epidermal keratinocytes regulate bacterial immune responses and host defense through EGFR
- Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib